ESR 精要:评估肝转移瘤对全身治疗影像学反应的实践推荐——欧洲胃肠道与腹部放射学会
欧洲胃肠道与腹部放射学会发布实践推荐,指出 RECIST 1.1 是评估肝转移瘤全身治疗后影像学反应的标准,推荐在特定临床场景(如转移性结直肠癌或转移性胃肠道间质瘤)使用经 CT 验证的替代标准(如 Chun 或 Choi 标准),并可将提示坏死、纤维化、钙化和出血的 CT 与 MR 改变作为肿瘤反应的辅助指标。
要点
- RECIST 1.1 推荐用于评估肝转移瘤全身治疗后的影像学反应。
- 特定场景(如转移性结直肠癌、转移性胃肠道间质瘤)推荐使用经 CT 验证的替代标准(如 Chun 或 Choi 标准)。
- 提示坏死、纤维化、钙化、出血的 CT 与 MR 改变可作为肿瘤反应的辅助指标。
核心结论
- RECIST 1.1 推荐用于评估肝转移瘤全身治疗后的影像学反应。
- 在特定临床场景(如转移性结直肠癌或转移性胃肠道间质瘤)推荐使用经 CT 验证的替代影像学标准(如 Chun 或 Choi 标准)。
- 提示纤维化、坏死、钙化和出血的 CT 与 MR 改变可作为肿瘤反应的辅助指标。
- 对于大小变化轻微的肝转移瘤,应系统评估替代标准和影像学表现,以更好地识别治疗应答者。
研究设计与样本
- 本文为欧洲胃肠道与腹部放射学会(ESR)发布的实践推荐。
关键影像表现/征象
- 靶向治疗和免疫治疗等新型治疗常引起肿瘤坏死、纤维化、囊性变、钙化及肝脏-肿瘤界面改变等超出体积缩小的变化。
- 上述形态学和强化改变可在 CT 和 MRI 上评估,可能更好反映特定临床场景下的生物学反应。
- CT 衰减、强化和肝脏/肿瘤界面可能与肿瘤反应的相关性优于体积缩小。
诊断标准与关键数值
- RECIST 1.1 基于病灶大小变化评估治疗反应,推荐用于评估肝转移瘤全身治疗后的影像学反应。
- 在特定临床场景(如转移性结直肠癌或转移性胃肠道间质瘤)推荐使用经 CT 验证的替代标准(如 Chun 或 Choi 标准)。
临床应用与阅片要点
- 评估肝转移瘤全身治疗反应时,RECIST 1.1 是推荐标准。
- 在转移性结直肠癌或转移性胃肠道间质瘤等特定场景,推荐使用经 CT 验证的替代标准(如 Chun 或 Choi 标准)。
- 应将提示纤维化、坏死、钙化和出血的 CT 与 MR 改变作为肿瘤反应的辅助指标进行系统评估。
- 对大小变化轻微的肝转移瘤,应系统评估替代标准和影像学表现,以更好地识别应答者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The liver is a common site for metastatic spread, especially in advanced colorectal, breast, and pancreatic cancers. Imaging evaluation of liver metastases after systemic treatments like chemotherapy, targeted therapy, or immunotherapy is essential to distinguish treatment response from disease progression. The widely used response evaluation criteria in solid tumours (RECIST 1.1) focus on lesion size changes to evaluate treatment response. However, newer therapies, mainly targeted therapy and immunotherapy, often induce changes beyond size reduction, such as tumour necrosis, fibrosis, cystic transformation, calcifications, and modifications at the liver-tumour interface. These morphological and enhancement changes can be evaluated on CT and MRI and may better reflect the biological response in specific clinical settings. Overall, RECIST 1.1 criteria are recommended for assessing the radiological response of liver metastases after systemic treatment. The use of alternative radiological criteria validated on CT (such as Chun or Choi criteria) is recommended in specific clinical settings (e.g. metastatic colorectal cancer or metastatic gastrointestinal stromal tumours). Additionally, CT and MR modifications that reflect fibrosis, necrosis, calcifications, and haemorrhage can serve as ancillary indicators of tumoural response. These alternative criteria and radiological findings should be systematically assessed, particularly in liver metastases with minimal size changes, to better identify responders. KEY POINTS: RECIST 1.1 is the standard for evaluating tumour response in solid tumours and is recommended for the assessment of liver metastases after systemic therapy. CT attenuation, enhancement, and liver/tumour interface may correlate better with tumoural response compared to size reduction. CT and MR changes suggesting necrosis, fibrosis, calcifications, and haemorrhage can be used as additional indicators of tumoural response.
引用
- Dioguardi Burgio M, Ronot M, Vilgrain V, et al. ESR Essentials: assessing the radiological response of liver metastases to systemic therapy-practice recommendations by the European Society of Gastrointestinal and Abdominal Radiology. Eur Radiol. 2025. PMID: 40185923. doi:10.1007/s00330-025-11540-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。